Home/Filings/4/0000899243-23-020438
4//SEC Filing

Davis Jefferson E 4

Accession 0000899243-23-020438

CIK 0001069308other

Filed

Nov 19, 7:00 PM ET

Accepted

Nov 20, 5:01 PM ET

Size

7.0 KB

Accession

0000899243-23-020438

Insider Transaction Report

Form 4
Period: 2023-11-17
Davis Jefferson E
Chief Business Officer
Transactions
  • Disposition to Issuer

    Common Stock, $0.0001 par value per share

    2023-11-1771,6450 total
Footnotes (3)
  • [F1]Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra.
  • [F2]Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company.
  • [F3](Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34.

Issuer

Acer Therapeutics Inc.

CIK 0001069308

Entity typeother

Related Parties

1
  • filerCIK 0001844533

Filing Metadata

Form type
4
Filed
Nov 19, 7:00 PM ET
Accepted
Nov 20, 5:01 PM ET
Size
7.0 KB